<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04769453</url>
  </required_header>
  <id_info>
    <org_study_id>NE 01021</org_study_id>
    <nct_id>NCT04769453</nct_id>
  </id_info>
  <brief_title>Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty</brief_title>
  <acronym>MAGIC</acronym>
  <official_title>Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty, Randomized, Controlled Trial: iTrack (Nova Eye Medical) Compared to Omni (Sight Sciences)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Eye, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Eye, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, randomized, single-masked clinical trial to evaluate the&#xD;
      effectiveness outcomes of ab-interno canaloplasty performed as a standalone procedure with&#xD;
      the iTrack surgical canaloplasty system to the Omni surgical system, and to compare the&#xD;
      effectiveness of two types of Ophthalmic Viscoelastic Device (OVD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in mean Intraocular pressure (IOP) and glaucoma medication use at 12 months post-intervention</measure>
    <time_frame>12 months</time_frame>
    <description>IOP will be measured at each study visit using Goldmann applanation tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications intra-operatively and post-operatively associated with the iTrack surgical system compared to complications intra-operatively and post-operatively with the OMNI surgical system.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity at 12 months compared to baseline visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Best corrected visual acuity (BCVA) will be assessed using the standard Snellen eye chart</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>iTrack surgical system with Healon GV Pro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to the iTrack surgical system (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMNI surgical system with Healon GV Pro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iTrack surgical system with Healon Pro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to the iTrack surgical system (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMNI surgical system with Healon Pro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ab-interno canaloplasty using the iTrack surgical system with Healon GV Pro</intervention_name>
    <description>360 degree microcatheterization and viscodilation of Schlemm's canal</description>
    <arm_group_label>iTrack surgical system with Healon GV Pro</arm_group_label>
    <other_name>ABiC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ab-interno canaloplasty using the Omni surgical system with Healon GV Pro</intervention_name>
    <description>360 degree microcatheterization and viscodilation of Schlemm's canal</description>
    <arm_group_label>OMNI surgical system with Healon GV Pro</arm_group_label>
    <other_name>ABiC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ab-interno canaloplasty using the iTrack surgical system with Healon Pro</intervention_name>
    <description>360 degree microcatheterization and viscodilation of Schlemm's canal</description>
    <arm_group_label>iTrack surgical system with Healon Pro</arm_group_label>
    <other_name>ABiC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ab-interno canaloplasty using the Omni surgical system with Healon Pro</intervention_name>
    <description>360 degree microcatheterization and viscodilation of Schlemm's canal</description>
    <arm_group_label>OMNI surgical system with Healon Pro</arm_group_label>
    <other_name>ABiC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with mild to moderate open angle Glaucoma.&#xD;
&#xD;
          2. Visual Field test (Humphrey SITA standard 24-2) with mean deviation better than or&#xD;
             equal to -12.0 dB&#xD;
&#xD;
          3. IOP &lt; or = to 36 mmHG while on one to four ocular hypotensive medications&#xD;
&#xD;
          4. Schaffer grade of &gt; or = III in all four quadrants&#xD;
&#xD;
          5. Able and willing to comply with the Protocol and follow up visits for 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Laser trabeculoplasty other than selective laser trabeculoplasty (SLT)&#xD;
&#xD;
          2. History of iStent or iStent inject within 180 days of the screening visit&#xD;
&#xD;
          3. History of ECP or Micropulse laser&#xD;
&#xD;
          4. Trabeculectomy or other bleb forming procedure including Xen, Express and glaucoma&#xD;
             drainage device/valves&#xD;
&#xD;
          5. Prior canaloplasty (ab interno and ab externo)&#xD;
&#xD;
          6. Prior goniotomy or trabeculotomy&#xD;
&#xD;
          7. History of Hydrus microstent or suprachoroidal stent&#xD;
&#xD;
          8. History of cataract surgery within 6 months of screening&#xD;
&#xD;
          9. Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular&#xD;
             glaucoma, pigmentary or pseudoexfoliative glaucoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shamil Patel, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Physicians and Surgeons of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Project Manager</last_name>
    <phone>1 (312) 927-9456</phone>
    <email>lrafol@nova-eye.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Advanced Eye Research Institute</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Institute of Ophthalmology</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Vision</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dean McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cataract and Laser Institute of Southern Oregon</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>El Paso Eye Surgeons</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eye Centers of Racine and Kenosha</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Canaloplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

